Eli Lilly and Company (NYSE:LLY) Shares Sold by Hamilton Capital LLC

Hamilton Capital LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 992 shares of the company’s stock after selling 15 shares during the period. Hamilton Capital LLC’s holdings in Eli Lilly and Company were worth $823,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. SGL Investment Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $241,000. EWA LLC raised its position in Eli Lilly and Company by 16.1% in the third quarter. EWA LLC now owns 1,227 shares of the company’s stock valued at $1,087,000 after purchasing an additional 170 shares during the period. Groupama Asset Managment lifted its stake in shares of Eli Lilly and Company by 0.5% during the third quarter. Groupama Asset Managment now owns 88,465 shares of the company’s stock worth $784,000 after purchasing an additional 458 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its position in shares of Eli Lilly and Company by 3.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 343,586 shares of the company’s stock worth $304,397,000 after buying an additional 11,273 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at about $14,078,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.1 %

Eli Lilly and Company stock opened at $826.71 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm’s 50-day moving average is $842.70 and its 200-day moving average is $872.01. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a market cap of $784.81 billion, a P/E ratio of 89.37, a PEG ratio of 3.13 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the firm posted $0.10 EPS. The business’s revenue was up 20.4% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.63%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Barclays decreased their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.